{
    "organizations": [],
    "uuid": "d21fc3a84f8f2a61cafc16f6b6679e7b1aabd33c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-us-fda-files-nda-under-priority-re/brief-u-s-fda-files-nda-under-priority-review-for-migalastat-idUSASB0C55S",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 12, 2018 / 12:51 PM / in 8 minutes BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Amicus Therapeutics Inc: \n* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE \n* AMICUS THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT GOAL DATE FOR FDA DECISION IS AUGUST 13, 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-02-12T20:51:00.000+02:00",
    "crawled": "2018-02-12T14:59:23.040+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "fda",
        "file",
        "nda",
        "priority",
        "review",
        "migalastat",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "amicus",
        "therapeutic",
        "inc",
        "fda",
        "file",
        "new",
        "drug",
        "application",
        "priority",
        "review",
        "migalastat",
        "treatment",
        "fabry",
        "disease",
        "amicus",
        "therapeutic",
        "inc",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "goal",
        "date",
        "fda",
        "decision",
        "august",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}